We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Less than a day after finalizing its acquisition of Allergan’s generics division, Israeli drugmaker Teva Pharmaceutical disclosed plans to pick up the company’s distribution arm for $500 million. Read More
The Chinese FDA has made sweeping reforms to the country’s nine-year-old drug registration rules, looking for industry feedback on a range of drug approval related revisions. Read More
The Bangladesh High Court has targeted 34 drug firms for ignoring an earlier ban on their products, demanding that they immediately recall their products. Read More
Spanish regulators are recommending EU officials suspend a manufacturing certificate from a Chinese API maker over repeated issues at its plant. Read More
The European Medicines Agency is recommending halting sales of 136 drugs whose approval came from flawed studies performed at the Semler Research Centre in India. Read More
With strong pipelines in Europe, Japan and the U.S., regenerative medicine is poised to become a $68 billion market in the next four years, according to a new report. Read More
The UK’s drug pricing watchdog has backed the reimbursement of five therapies by NHS England, provided the companies offer the drugs at discounted prices. Read More
After nearly two years, the EMA is formalizing its iterative pathway program that saw six applications progress to formal advice from the agency. Read More